Jason Coloma, Maze Therapeutics CEO
January 7, 2025 05:36 PM EST
Financing
Startups

Maze files for first biotech IPO of 2025, fol­low­ing $115M fund­ing boost

Kyle LaHucik

Senior Reporter

Maze Ther­a­peu­tics has sub­mit­ted its pitch for an ini­tial pub­lic of­fer­ing af­ter dis­clos­ing a $115 mil­lion Se­ries D …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Gala­pa­gos to split in­to two com­pa­nies, slash head­count as it eyes turn­around

Vir’s ear­ly T cell en­gager da­ta of­fer first look at can­cer piv­ot, stock jumps

ARCH, F-Prime and Mubadala pump $200M in­to for­mer De­nali pro­grams

Every FDA drug ap­proval from 2024: Few­er nods, but long-await­ed treat­ments cross the fin­ish line

Sana’s stock soars on new cell ther­a­py da­ta; UniQure’s $75M of­fer­ing

FDA sets an ef­fi­ca­cy thresh­old for fu­ture weight loss drugs

A service from the Financial Times